secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001171843-23-003041
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corvus reports Q1 net loss of $7.9M; CPI-818 shows 6/13 ORR in ALC>900 TCL patients
--------------------------------------------------------------------------------

- Net loss of $7.9M vs $8.3M in Q1 2022; cash & securities $34.5M as of March 31, 2023.
- CPI-818 Phase 1/1b TCL: 2 CR, 1 nodal CR, 3 PR among 19 evaluable; 9 patients remain on therapy.
- ALC>900 biomarker selected 6/13 ORR; median PFS 19.9 months for ALC>900 vs 2.1 months for <900.
- CFO expects FY2023 net cash use of $19-22M; projected year-end cash of $20-23M funding into 2024.
- Plans to meet with FDA in Q3 2023 to discuss potential registrational Phase 3 trial for CPI-818.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/0001171843-23-003041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000117184323003041/f8k_050823.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-003041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer